Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin

Cell Proliferation

Volumn 42, Issue 4, 2009, Pages 554-561

  Andreucci, M ^a   Fuiano, G ^a   Presta, P ^a   Lucisano, G ^a   Leone, F ^a   Fuiano, L ^a   Bisesti, V ^b   Esposito, P ^b   Russo, D ^b   Memoli, B ^b   Faga, T ^a   Michael, A ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ERYTHROPOIETIN; ERYTHROPOIETIN; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROGEN PEROXIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL DAMAGE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EPITHELIUM; SIGNAL TRANSDUCTION;

CELL LINE; CELL SURVIVAL; ERYTHROPOIETIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYDROGEN PEROXIDE; KIDNEY TUBULES, PROXIMAL; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 67649889250     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2009.00617.x     Document Type: Article

References (45)

1. Braga M, Gianotti L, Gentilini O, Vignali A, Corizia L, Di Carlo V (1999) Erythropoiesis after therapy with recombinant human erythropoietin: a dose-response study in anemic cancer surgery patients. Vox Sang. 76, 38-42.
2. Fisher JW (1998) A quest for erythropoietin over nine decades. Annu. Rev. Pharmacol. Toxicol. 38, 1-20.
3. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 91, 3974-3978.
4. Chong ZZ, Kang JQ, Maiese K (2002) Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother. Stem Cell Res. 11, 863-871.
5. Westenfelder C, Biddle DL, Baranowski RL (1999) Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 55, 808-820.
6. Chong ZZ, Kang JQ, Maiese K (2003) Erythropoietin: cytoprotection in vascular and neuronal cells. Curr. Drug Targets Cardiovasc. Haematol. Disord. 3, 141-154.
7. Sasaki R (2003) Pleiotropic functions of erythropoietin. Intern. Med. 42, 142-149.
8. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, Jaudon MC, Bourbouze R, Jacobs C, Deray G (2001) Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol. Dial. Transplant. 16, 932-938.
9. Sharpies EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM (2004) Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am. Soc. Nephrol. 15, 2115-2124.
10. Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D (2006) Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol. Dial. Transplant. 21, 330-336.
11. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW (2004) Erythropoietin protects against ischaemic acute renal injury. Nephrol. Dial. Transplant. 19, 348-355.
12. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, Sun BK, Kim YS, Kim J, Chang YS, Bang BK (2003) Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 17, 1754-1755.
13. Sharpies EJ, Thiemermann C, Yaqoob MM (2005) Mechanisms of disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat. Clin. Pract. Nephrol. 1, 87-97.
14. Johnson KJ, Weinberg JM (1993) Postischemic renal injury due to oxygen radicals. Curr. Opin. Nephrol. Hypertens. 2, 625-635.
15. Rampino T, Collesi C, Gregorini M, Maggio M, Soccio G, Guallini P, Dal Canton A (2002) Macrophage-stimulating protein is produced by tubular cells and activates mesangial cells. J. Am. Soc. Nephrol. 13, 2649-2657.
16. Andreucci M, Fuiano G, Presta P, Esposito P, Faga T, Bisesti V, Procino A, Altieri V, Tozzo C, Memoli B, Michael A (2006) Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells. Biochem. Pharmacol. 72, 1334-1342.
17. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol. Methods 65, 55-63.
18. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
19. 1 cells result in phosphorylation of FKHR and FKHRL1. Kidney Int. 64, 1189-1198.
20. Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433, 477-480.
21. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868.
22. Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK (2003) Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab. Clin. Med. 142, 178-186.
23. Greene EL, Paller MS (1991) Oxygen free radicals in acute renal failure. Miner. Electrolyte Metab. 17, 124-132.
24. Paller MS (1992) Free radical-mediated postischemic injury in renal transplantation. Ren. Fail. 14, 257-260.
25. Fatokun AA, Stone TW, Smith RA (2007) Hydrogen peroxide mediates damage by xanthine and xanthine oxidase in cerebellar granule neuronal cultures. Neurosci. Lett. 416, 34-38.
26. 2 injury in primary cultured alveolar epithelial cells. J Control. Release 121, 74-80.
27. Sugino N (2007) The role of oxygen radical-mediated signaling pathways in endometrial function. Placenta 28(Suppl. A), S133-S136.
28. Zhang W, Wang M, Xie HY, Zhou L, Meng XQ, Shi J, Zheng S (2007) Role of reactive oxygen species in mediating hepatic ischemia-reperfusion injury and its therapeutic applications in liver transplantation. Transplant. Proc. 39, 1332-1337.
29. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927.
30. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.
31. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185.
32. Pap M, Cooper GM (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol. Chem. 273, 19929-19932.
33. Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A (2006) Glycogen synthase kinase-3β inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor NrfG. J Biol. Chem. 281, 14841-14851.
34. 2 cytotoxicity in mouse renal proximal tubule cells. Kidney Int. 65, 1231-1239.
35. Kashii Y, Uchida M, Kirito K, Tanaka M, Nishijima K, Toshima M, Ando T, Koizumi K, Endoh T, Sawada K, Momoi M, Miura Y, Ozawa K, Komatsu N (2000) A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 96, 941-949.
36. 2-induced mitosis. J Cell Biochem. 91, 1293-1300.
37. Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 116, 1175-1186.
38. Hausenloy DJ, Mocanu MM, Yellon DM (2004) Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc. Res. 63, 305-312.
39. Brines M, Cerami A (2006) Discovering erythropoietin's extrahematopoietic functions: biology and clinical promise. Kidney Int. 70, 246-250.
40. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. USA 101, 14907-14912.
41. Drüeke T (2001) Hyporesponsiveness to recombinant human erythropoietin. Nephrol. Dial. Transplant. 16(Suppl. 7), 225-228.
42. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl. J Med. 355, 2071-2084.
43. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J Med. 355, 2085-2098.
44. Levin A (2007) Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol. Dial. Transplant. 22, 309-312.
45. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC (2007) Haemoglobin targets: we were wrong, time to move on. Lancet 369, 346-350.